Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Abstract Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in inflamed STS which are characterized by the presence of tertiary lymphoid structure...
Main Authors: | Mariella Spalato-Ceruso, Fanny Bouteiller, Jean-Philippe Guegan, Maud Toulmonde, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, François Le Loarer, Berengere Dadone-Montaudie, Marina Pulido, Antoine Italiano |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | https://doi.org/10.1186/s13045-022-01377-2 |
Similar Items
-
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study
by: Cheng-Ming Sun, et al.
Published: (2024-02-01) -
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
by: Maud Toulmonde, et al.
Published: (2024-02-01) -
782-G The correlation of tumor immune microenvironment with response to neoadjuvant chemotherapy response in undifferentiated pleiomorphic sarcomas: an analysis of the NEOSARCOMICS study
by: Jean-Michel Coindre, et al.
Published: (2023-11-01) -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
by: Maud Toulmonde, et al.
Published: (2022-10-01) -
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
by: Sophie Cousin, et al.
Published: (2022-12-01)